Two Approaches to Growth Hormone Research
Ipamorelin and sermorelin represent two distinct pharmacological approaches to stimulating growth hormone release — through the ghrelin receptor (GHS-R) and the GHRH receptor, respectively. This comparison examines their mechanisms, dosing, and research applications.
Mechanism Comparison
Ipamorelin (GHRP Class)
Ipamorelin is a selective ghrelin mimetic that binds GHS-R1a receptors on pituitary somatotrophs. It triggers acute, pulsatile GH release with remarkable selectivity — stimulating GH without significantly affecting ACTH, cortisol, or prolactin.
Sermorelin (GHRH Analog)
Sermorelin is a truncated form of GHRH (first 29 amino acids) that binds GHRH receptors on the pituitary. It stimulates GH synthesis and release through the physiological GHRH pathway. Note: CJC-1295 No DAC (Modified GRF 1-29) is the stabilized, more potent version of sermorelin.
Comparison Table
| Parameter | Ipamorelin | Sermorelin |
|---|---|---|
| Receptor target | GHS-R1a (ghrelin) | GHRH receptor |
| Mechanism | Ghrelin mimetic | GHRH analog |
| Selectivity | Highly selective for GH | GH + some cortisol effect |
| Typical dose | 200-300mcg 2-3x daily | 200-300mcg before bed |
| Half-life | ~2 hours | ~10-20 minutes |
| Best combined with | GHRH analogs (CJC-1295) | GHRPs (ipamorelin) |
Synergistic Potential
The most powerful insight from GH peptide research is that GHRP + GHRH combinations produce synergistic — not merely additive — GH release. Ipamorelin + CJC-1295 No DAC (the improved sermorelin) is the most commonly studied combination. See Ipamorelin vs CJC-1295.
Why CJC-1295 No DAC Replaced Sermorelin
Sermorelin has a very short half-life (~10-20 minutes) due to rapid DPP-IV enzymatic degradation. CJC-1295 No DAC includes amino acid substitutions that resist DPP-IV, extending the half-life to ~30 minutes and improving GH pulse amplitude. Most modern research uses CJC-1295 No DAC instead of sermorelin.
For research purposes only. Ipamorelin and CJC-1295 No DAC available. Visit COAs.